CRIS

What CRIS does

Consortium for Clinical Research and Innovation, Singapore (CRIS) is a Singapore government agency consortium established in 2020 and wholly owned by MOH Holdings Pte Ltd, the holding company of Singapore's Ministry of Health. CRIS coordinates seven national R&D and clinical translation programmes as distinct business units under a common governance structure: the Singapore Clinical Research Institute (SCRI) for clinical trial design and coordination; the National Health Innovation Centre (NHIC) for health technology commercialization funding; the Advanced Cell Therapy and Research Institute (ACTRIS) for GMP-compliant cell and gene therapy manufacturing; Precision Health Research Singapore (PRECISE) for population genomics and precision medicine; the Singapore Translational Cancer Consortium (STCC) for oncology research coordination; the Cardiovascular Disease National Collaborative Enterprise (CADENCE) for cardiovascular research; and the Singapore Medical Foundation AI Model (SIMFONI) for AI deployment in healthcare.

CRIS does not commercialize products or services. Its operations are funded through Singapore's Research, Innovation and Enterprise (RIE) frameworks administered via MOH Holdings, making it functionally a government grant-funded coordination entity. Its primary "customers" in an operational sense are Singapore's three public healthcare clusters (NHG Health, NUHS, SingHealth), academic researchers, and biopharmaceutical industry partners seeking to conduct clinical research in Singapore. The consortium manages 11+ clinical research networks, a 1,450 sqm cell therapy manufacturing facility with 14 GMP-compliant clean suites, and a population genomic dataset covering 100,000 Singaporean participants (SG100K).

CRIS's core technology assets include its national clinical research network infrastructure, the SG100K genomic dataset (Southeast Asia's most comprehensive consented population study), GMP-certified cell therapy manufacturing capabilities, and an expanding portfolio of AI-driven healthcare initiatives. The entity pursues an event-driven go-to-market model centered on the CRIS Connect webinar series, participation in major conferences such as SWITCH (Singapore Week of Innovation & Technology), annual scientific symposiums, and strategic MoU-based partnerships with international biopharmaceutical companies and public health organizations across APAC.

Name

CRIS

Legal name

Consortium for Clinical Research and Innovation, Singapore

Website

https://cris.sg

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

101–250 employees

Short description

CRIS is a Singapore government agency consortium coordinating seven national clinical research and translation programmes across clinical trials, precision medicine, cell therapy, cancer, cardiovascular, and AI health, serving public healthcare institutions, academic researchers, and biopharmaceutical partners.

Ownership category

akta.pro rank

Product category

Clinical Research Services

NAICS

Research and Development in the Physical, Engineering, and Life Sciences (54171), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

akta.pro primary industry

Clinical CROs (Phase I–IV) (HLAGAAAA)

akta.pro secondary industries

Specialty Therapeutic-Area CROs (e.g., oncology/rare disease) (HLAGAAAL), Clinical Data Management, Biostatistics & Statistical Programming CROs (HLAGAAAF), Real-World Evidence (RWE), HEOR & Epidemiology CROs (HLAGAAAK), Patient Recruitment, Site Feasibility & Trial Enablement CROs (HLAGAAAI), Central Laboratory & Clinical Trial Testing CROs (HLAGAAAE)

Keywords

• Clinical research services
• Clinical trial coordination
• Precision medicine programs
• Cell therapy manufacturing
• Health innovation funding

Headquarters

HQ city

Singapore

HQ country

Singapore

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Government Funding: CRIS operates as a government-funded consortium under the Ministry of Health Holdings (MOHH), receiving funding through Research, Innovation and Enterprise (RIE) frameworks to support national clinical research and translation programs.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Core offering

CRIS is a Singapore government consortium that coordinates seven national R&D and clinical translation programmes. It provides clinical trial coordination and design support (SCRI), translational funding for healthtech innovation (NHIC), GMP-compliant cell and gene therapy manufacturing (ACTRIS), national precision medicine and population genomics (PRECISE), translational cancer research coordination (STCC), cardiovascular research collaboration (CADENCE), and AI model deployment in healthcare (SIMFONI).

Product overview

CRIS operates as a consortium bringing together seven national R&D and clinical translation programmes as distinct business units under common management and governance. The portfolio includes: Singapore Clinical Research Institute (SCRI) for clinical trials support; National Health Innovation Centre (NHIC) for health tech innovation funding; Advanced Cell Therapy and Research Institute (ACTRIS) for cell and gene therapy manufacturing; Precision Health Research Singapore (PRECISE) for precision medicine and genomics; Singapore Translational Cancer Consortium (STCC) for cancer research coordination; Cardiovascular Disease National Collaborative Enterprise (CADENCE) for cardiovascular research; and SIMFONI for AI in healthcare. These programmes collectively advance Singapore's clinical research and innovation capabilities through facilitated collaborations with research and biomedical entities across public sector and industry.

Differentiator

Problem solved

Functional benefit

Products and services

• Singapore Clinical Research Institute (SCRI) Singapore's academic research organisation dedicated to improving patient care through design and support of cutting-edge clinical trials and research; coordinates 11+ clinical research networks across public healthcare clusters for pharmaceutical, medical device, biotech, and public sector investigators.
• National Health Innovation Centre Singapore (NHIC) Provides translational funding and strategic guidance to accelerate development of innovative health technologies and services from Singapore's public healthcare sector; has delivered over 85 licenses and 28 spin-offs across three RIE cycles.
• Advanced Cell Therapy and Research Institute Singapore (ACTRIS) National facility for end-to-end cell therapy development and manufacturing, supporting translation of innovations into clinical care for cancer treatment and regenerative medicine. Operates 14 GMP-compliant clean suites across 1,450 sqm; holds GMP certification and Manufacturer's License from HSA granted February 2025.
• Precision Health Research Singapore (PRECISE) Central entity coordinating Singapore's National Precision Medicine strategy; implements population genomic studies and pilots precision medicine in clinical practice. Manages the SG100K dataset covering 100,000 Singaporeans and integrated lifestyle/clinical data.
• Singapore Translational Cancer Consortium (STCC) Coordinates collaborative investigator-led cancer research across Singapore's public healthcare and academic institutions; strengthens translational research platforms and fosters strategic partnerships in oncology.
• Cardiovascular Disease National Collaborative Enterprise (CADENCE) Integrates existing research capabilities across academic and public health institutes to advance Singapore's position in cardiovascular research, with focus on cardiometabolic diseases. Leads the regional ASPIRE Network across APAC.
• Singapore Medical Foundation AI Model (SIMFONI) Programme advancing effective, safe and responsible use of AI in Singapore's healthcare systems; supports healthcare professionals and empowers patients through deployment of foundation AI models in clinical settings.

Quantifiable outcome

• Over 85 licenses and 28 spin-offs delivered across three RIE cycles through NHIC
• +2 more outcomes

Named customers4 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature4 records

Partnerships

Ten partnerships are on record, tiered flagship, core and minor.

• Alnylam, Bayer, Boehringer Ingelheim, Novo NordiskflagshipStrategic or Co-development Partner · 1 December 2025PRECISE announced landmark partnership with four major pharmaceutical companies to advance Asian precision medicine research. The collaboration enhances existing PRECISE-SG100K anonymized datasets and generates high-quality research to benefit Asia and Asians worldwide.
• NHG Health, National University Health System, SingHealthflagshipStrategic or Co-development Partner · 14 November 2025PRECISE signed MoU with three public healthcare clusters for Phase III of National Precision Medicine programme. Partnership aims to scale research insights into tangible healthcare outcomes through patient cohort genomic studies.
• MedTech CatapultcoreStrategic or Co-development Partner · 25 August 2025NHIC and SCRI signed MoU with MedTech Catapult to catalyze synergy across the MedTech ecosystem. The partnership strengthens clinical development and market adoption for innovators and academic spinoffs through unmet need validation, productization support, and clinical study planning.
• Novo NordiskcoreStrategic or Co-development Partner · 9 May 2025CADENCE signed MoU with Novo Nordisk to strengthen collaboration in clinical research for cardiometabolic diseases. Partnership aims to bring more trials into Singapore, broaden patient access to innovative therapies, and strengthen trial site capabilities.
• National Health Research Institutes (NHRI), TaiwancoreStrategic or Co-development Partner · 27 March 2025STCC signed MoU with NHRI in Taiwan to strengthen cross-border partnerships in biobanking and translational cancer research. The partnership enriches STCC's cancer tissue specimen repository and enables researchers from Singapore and Taiwan to co-access anonymized biospecimens for Asian-prevalent cancers.
• IlluminaflagshipStrategic or Co-development Partner · 26 May 2022PRECISE and Illumina announced strategic partnership to sequence and analyze 100,000 Singaporean whole genomes (SG100K). Partnership creates Southeast Asia's most comprehensive consented population study yielding insights into Asian-specific diseases.
• NovogeneAIT Genomics SingaporecoreTechnology or Integration · 26 May 2022Appointed by Illumina to carry out genome sequencing for 100,000 individuals as part of SG100K project. One of the largest Next-Generation Sequencing service providers in Asia.
• NUS Yong Loo Lin School of MedicinecoreStrategic or Co-development Partner · 6 April 2022ACTRIS and NUS jointly launched professional certification course on principles and practice of cell therapy - first of its kind in Asia - to equip healthcare professionals with training in immunotherapeutics.
• XNode, A*StartCentralminorStrategic or Co-development Partner · 23 March 2021Singapore Deep-Tech Alliance launched venture builder SDTA22 powered by XNode, partnering with A*StartCentral and NHIC to drive sustainability through Industry 4.0 transformation, including healthtech ventures.
• Roche, National Cancer Centre Singapore, National University Cancer InstitutecoreStrategic or Co-development Partner · 9 February 2021STCC, NCCS, NCIS and Roche signed MoU to leverage data insights and deepen understanding of disease drivers. Partnership builds clinico-genomic database combining clinical insights with real-world evidence to improve patient outcomes through precision oncology.

Scale indicators8 records

Recent moves7 records

Expansion highlights6 records

Regional players

• Korea National Institute of Health (KNIH): South Korea's national public health and disease control institute, coordinating government-funded biomedical R&D and population health research. Operates a similar mandate to the SCRI and PRECISE programs in a comparable APAC health system, though with a stronger infectious disease focus.
• CMIC Group: Japan's largest CRO, providing clinical trial services, site management, and data analytics primarily to Japanese and APAC biopharma sponsors. Comparable as an Asia-based clinical research services provider, though it is a commercial entity rather than a government consortium.

Broad incumbents

• WuXi AppTec: China-based global CRO/CDMO with extensive Asia presence spanning clinical trial services, biologics manufacturing, and genomics. Comparable in scale and breadth to the full CRIS consortium, and a direct competitor in the cell therapy manufacturing (vs. ACTRIS) and genomic services (vs. PRECISE) domains.
• National Health and Medical Research Council (NHMRC): Australia's primary government body for medical and health research funding and strategic guidance, comparable in mandate to MOH's oversight of CRIS. Anchors a national research funding framework and clinical trial policy across multiple therapeutic areas, similar in regulatory role though not in operational trial execution.
• IQVIA: World's largest commercial CRO with full-service clinical trial, real-world evidence, and biostatistics capabilities across all major geographies. The dominant alternative for pharma sponsors running global trials that may include Singapore sites, and the principal commercial competitor for industry-sponsored flow that SCRI and ACTRIS target.

Direct peers

• Singapore-MIT Alliance for Research and Technology (SMART): Joint research enterprise between MIT and the Singapore research ecosystem, operating multiple interdisciplinary research groups including in healthcare and biotechnology. Closest structural analogue in Singapore to CRIS's consortium-coordination model, anchoring public-sector research at scale with international university and government backing.
• National Health Research Institutes (NHRI), Taiwan: Taiwan's national health research institutes focused on biomedical and translational research. Active CRIS partner under the March 2025 STCC MoU for biobanking and translational cancer research; operates a similar model combining government funding, multi-institution coordination, and population-scale biomedical programs in APAC.
• Agency for Science, Technology and Research (A*STAR): Singapore's lead public-sector R&D agency, parent of entities like the Genome Institute of Singapore and Experimental Biotherapeutics Centre. Most directly comparable peer given its government-mandated role coordinating biomedical R&D in Singapore and the institutional overlap with several CRIS program leaders (including Dr Danny Soon and Professor Robert Morris).

Emerging players

• EPS Corporation: Japan-headquartered clinical research and site management organization with growing APAC presence. Comparable as a regional player in clinical trial enablement and patient recruitment, the same domain where SCRI's 11+ clinical research networks operate in Singapore.

Others

• MOH Office for Healthcare Transformation (MOHT): Singapore government entity that prototypes and scales healthcare transformation initiatives, including the mindline.sg population platform. Shares the same government ecosystem as CRIS, employs SIMFONI's incoming ED Professor Robert Morris in his prior role, and is a natural partner/adjacent entity to CRIS's NHIC and SIMFONI programs.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/crissg

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CRIS